Takeda Korea said it has appointed Kim Mi-seung as the new head of its oncology business unit, effective Tuesday.

Kim brings over two decades of experience across the pharmaceutical and healthcare sectors, both in Korea and abroad. Her expertise spans oncology-focused marketing, medical affairs, and scientific sales functions, with a proven track record of leading cross-functional collaboration and driving performance.

Most recently, she led the oncology business unit at Amgen Korea, where she played a pivotal role in launching new cancer therapies and devising strategies for brand growth.

Before Amgen, she held key roles in the oncology divisions of multiple multinational pharmaceutical companies, including BMS Korea and Novartis Korea, where she spearheaded market entry and commercial success for various cancer treatments.

Kim also has a clinical background, serving as a clinical pharmacist at Samsung Medical Center and the National Cancer Center.

The new oncology head holds a bachelor’s degree in pharmacy from Chung-Ang University and completed the Global Executive MBA program jointly offered by Sungkyunkwan University and Indiana University’s Kelley School of Business.

Kim is also a Board Certified Oncology Pharmacist (BCOP), a U.S.-based certification recognizing advanced expertise in oncology pharmacotherapy.

“The Oncology Business Unit is a key pillar of Takeda Korea’s strategic growth, playing a central role in advancing innovation and treatment accessibility for patients,” Takeda Korea General Manager Park Kwang-kyu said. “We believe Kim, with her comprehensive experience and integrated leadership in the oncology field, will enhance our business competitiveness and help deliver innovative therapeutic options to more patients.”

Commenting on her new role, Kim said, “Oncology is directly linked to patients’ survival, and I believe therapeutic value must go hand in hand with a patient-centric philosophy.”

Kim stressed that she will leverage her experience across the field and industry to expand access to innovative treatments and lead the business unit strategically, ensuring that Takeda Korea remains a trusted partner to both patients and healthcare professionals.